Scarab Genomics and Neoclone sign license agreement

Sep 11 2009

Scarab Genomics, a leader in E coli technology, has entered into a license agreement with NeoClone to market and distribute their proprietary antibodies against Shiga toxin. “We are confident the research and diagnostic markets will welcome access to these high quality reagents,” according to Frederick R. Blattner, PhD, founder and President of Scarab Genomics. Shiga toxin is secreted by E. coli bacteria, which can cause disease or even death when consumed, most often in undercooked hamburgers. The study of it is important because at present time there is no treatment; antibiotics actually cause an increase in the toxin and just make things worse. While the specifics of the agreement were not disclosed, both companies have indicated that the cost in developing the antibodies and the revenues will be shared. “Given Scarab’s deep expertise in this area, we (NeoClone) are very excited to have them as a commercial partner,” stated Deven McGlenn, NeoClone’s CEO. More information and to order these antibodies go to www.neoclone.com.

http://www.scarabgenomics.com/